Cargando…

Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma

Liver cancer is the second leading cause of cancer-related deaths worldwide, and hepatocellular carcinoma is the most common type. The pathogenesis of hepatocellular carcinoma is concealed, its progress is rapid, its prognosis is poor, and the mortality rate is high. Therefore, novel molecular targe...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Meng, Zhang, Hailing, Zheng, Jianming, Liu, Yangfang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052944/
https://www.ncbi.nlm.nih.gov/pubmed/32127929
http://dx.doi.org/10.7150/jca.39972
_version_ 1783502950706970624
author Guo, Meng
Zhang, Hailing
Zheng, Jianming
Liu, Yangfang
author_facet Guo, Meng
Zhang, Hailing
Zheng, Jianming
Liu, Yangfang
author_sort Guo, Meng
collection PubMed
description Liver cancer is the second leading cause of cancer-related deaths worldwide, and hepatocellular carcinoma is the most common type. The pathogenesis of hepatocellular carcinoma is concealed, its progress is rapid, its prognosis is poor, and the mortality rate is high. Therefore, novel molecular targets for hepatocellular carcinoma early diagnosis and development of targeted therapy are critically needed. Glypican-3, a cell-surface glycoproteins in which heparan sulfate glycosaminoglycan chains are covalently linked to a protein core, is overexpressed in HCC tissues but not in the healthy adult liver. Thus, Glypican-3 is becoming a promising candidate for liver cancer diagnosis and immunotherapy. Up to now, Glypican-3 has been a reliable immunohistochemical marker for hepatocellular carcinoma diagnosis, and soluble Glypican-3 in serum has becoming a promising marker for liquid biopsy. Moreover, various immunotherapies targeting Glypican-3 have been developed, including Glypican-3 vaccines, anti- Glypican-3 immunotoxin and chimeric-antigen-receptor modified cells. In this review, we summarize and analyze the structure and physicochemical properties of Glypican-3 molecules, then review their biological functions and applications in clinical diagnosis, and explore the diagnosis and treatment strategies based on Glypican-3.
format Online
Article
Text
id pubmed-7052944
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-70529442020-03-03 Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma Guo, Meng Zhang, Hailing Zheng, Jianming Liu, Yangfang J Cancer Review Liver cancer is the second leading cause of cancer-related deaths worldwide, and hepatocellular carcinoma is the most common type. The pathogenesis of hepatocellular carcinoma is concealed, its progress is rapid, its prognosis is poor, and the mortality rate is high. Therefore, novel molecular targets for hepatocellular carcinoma early diagnosis and development of targeted therapy are critically needed. Glypican-3, a cell-surface glycoproteins in which heparan sulfate glycosaminoglycan chains are covalently linked to a protein core, is overexpressed in HCC tissues but not in the healthy adult liver. Thus, Glypican-3 is becoming a promising candidate for liver cancer diagnosis and immunotherapy. Up to now, Glypican-3 has been a reliable immunohistochemical marker for hepatocellular carcinoma diagnosis, and soluble Glypican-3 in serum has becoming a promising marker for liquid biopsy. Moreover, various immunotherapies targeting Glypican-3 have been developed, including Glypican-3 vaccines, anti- Glypican-3 immunotoxin and chimeric-antigen-receptor modified cells. In this review, we summarize and analyze the structure and physicochemical properties of Glypican-3 molecules, then review their biological functions and applications in clinical diagnosis, and explore the diagnosis and treatment strategies based on Glypican-3. Ivyspring International Publisher 2020-02-03 /pmc/articles/PMC7052944/ /pubmed/32127929 http://dx.doi.org/10.7150/jca.39972 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Review
Guo, Meng
Zhang, Hailing
Zheng, Jianming
Liu, Yangfang
Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma
title Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma
title_full Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma
title_fullStr Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma
title_full_unstemmed Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma
title_short Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma
title_sort glypican-3: a new target for diagnosis and treatment of hepatocellular carcinoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052944/
https://www.ncbi.nlm.nih.gov/pubmed/32127929
http://dx.doi.org/10.7150/jca.39972
work_keys_str_mv AT guomeng glypican3anewtargetfordiagnosisandtreatmentofhepatocellularcarcinoma
AT zhanghailing glypican3anewtargetfordiagnosisandtreatmentofhepatocellularcarcinoma
AT zhengjianming glypican3anewtargetfordiagnosisandtreatmentofhepatocellularcarcinoma
AT liuyangfang glypican3anewtargetfordiagnosisandtreatmentofhepatocellularcarcinoma